Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)
Rituximab is a chemeric murine/human anti-B lymphocyte antigen CD20 monoclonal antibody used in the treatment of rheumatoid arthritis resistant to treatment by one or more anti TNF-alpha therapies (1). The recommended dose for an efficient depletion of the B CD 20 lymphocytes in rheumatoid arthritis...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-06-01
|
| Series: | Reumatismo |
| Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/454 |
| _version_ | 1811302660163239936 |
|---|---|
| author | V. Bruzzese J. Pepe |
| author_facet | V. Bruzzese J. Pepe |
| author_sort | V. Bruzzese |
| collection | DOAJ |
| description | Rituximab is a chemeric murine/human anti-B lymphocyte antigen CD20 monoclonal antibody used in the treatment of rheumatoid arthritis resistant to treatment by one or more anti TNF-alpha therapies (1). The recommended dose for an efficient depletion of the B CD 20 lymphocytes in rheumatoid arthritis is two infusions of 1000 mg, with the second infusion being administered two weeks after the first. At this dose, one obtains a rapid and persistent depletion of CD 20 cells, with repopulation occurring, on the average, in about eight months (2). Here, we present a case of a woman treated with only 50 mg of rituximab, who underwent both a rapid and pronounced reduction of B CD 20 lymphocytes... |
| first_indexed | 2024-04-13T07:33:11Z |
| format | Article |
| id | doaj.art-0b616c09ea3540299a19c49253e979ec |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-04-13T07:33:11Z |
| publishDate | 2011-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-0b616c09ea3540299a19c49253e979ec2022-12-22T02:56:16ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-06-0161430630810.4081/reumatismo.2009.306Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)V. BruzzeseJ. PepeRituximab is a chemeric murine/human anti-B lymphocyte antigen CD20 monoclonal antibody used in the treatment of rheumatoid arthritis resistant to treatment by one or more anti TNF-alpha therapies (1). The recommended dose for an efficient depletion of the B CD 20 lymphocytes in rheumatoid arthritis is two infusions of 1000 mg, with the second infusion being administered two weeks after the first. At this dose, one obtains a rapid and persistent depletion of CD 20 cells, with repopulation occurring, on the average, in about eight months (2). Here, we present a case of a woman treated with only 50 mg of rituximab, who underwent both a rapid and pronounced reduction of B CD 20 lymphocytes...http://www.reumatismo.org/index.php/reuma/article/view/454 |
| spellingShingle | V. Bruzzese J. Pepe Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) Reumatismo |
| title | Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) |
| title_full | Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) |
| title_fullStr | Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) |
| title_full_unstemmed | Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) |
| title_short | Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) |
| title_sort | unexpected and persistent depletion of b lymphocytes cd20 following a minimum dose of anti cd20 antibody rituximab |
| url | http://www.reumatismo.org/index.php/reuma/article/view/454 |
| work_keys_str_mv | AT vbruzzese unexpectedandpersistentdepletionofblymphocytescd20followingaminimumdoseofanticd20antibodyrituximab AT jpepe unexpectedandpersistentdepletionofblymphocytescd20followingaminimumdoseofanticd20antibodyrituximab |